These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31505315)

  • 1. Host genetic background affects the course of infection and treatment response in patients with chronic hepatitis B.
    Rybicka M; Woziwodzka A; Romanowski T; Sznarkowska A; Stalke P; Dręczewski M; Bielawski KP
    J Clin Virol; 2019 Nov; 120():1-5. PubMed ID: 31505315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in sodium taurocholate cotransporting polypeptide are not associated with hepatitis B virus clearance in Chinese Tibetans and Uygurs.
    Su Z; Li Y; Liao Y; Cai B; Chen J; Zhang J; Li L; Ying B; Tao C; Zhao M; Ba Z; Zhang Z; Wang L
    Infect Genet Evol; 2016 Jul; 41():128-134. PubMed ID: 27051045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Treeprasertsuk S; Tanwandee T; Charatcharoenwitthaya P; Thongsawat S; Leerapun A; Piratvisuth T; Boonsirichan R; Bunchorntavakul C; Pattanasirigool C; Pornthisarn B; Tuntipanichteerakul S; Sripariwuth E; Jeamsripong W; Sanpajit T; Poovorawan Y; Komolmit P
    Antivir Ther; 2018; 23(1):67-75. PubMed ID: 28635613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of NTCP polymorphisms with clinical outcome of hepatitis B infection in Thai individuals.
    Chuaypen N; Tuyapala N; Pinjaroen N; Payungporn S; Tangkijvanich P
    BMC Med Genet; 2019 May; 20(1):87. PubMed ID: 31117968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Hu HH; Liu J; Lin YL; Luo WS; Chu YJ; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; You SL; Yang HI; Chen CJ;
    Gut; 2016 Sep; 65(9):1514-21. PubMed ID: 26642861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse Effects of the NTCP p.Ser267Phe Variant on Disease Progression During Chronic HBV Infection and on HBV preS1 Variability.
    Yang F; Wu L; Xu W; Liu Y; Zhen L; Ning G; Song J; Jiao Q; Zheng Y; Chen T; Xie C; Peng L
    Front Cell Infect Microbiol; 2019; 9():18. PubMed ID: 30881922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.
    Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L
    Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
    Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the gene polymorphisms in sodium taurocholate cotransporting polypeptide with the outcomes of hepatitis B infection in Chinese Han population.
    Su Z; Li Y; Liao Y; Cai B; Chen J; Zhang J; Li L; Ying B; Tao C; Wang L
    Infect Genet Evol; 2014 Oct; 27():77-82. PubMed ID: 25010264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
    Yu SL; Guo CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B.
    Limothai U; Chuaypen N; Khlaiphuengsin A; Chittmittraprap S; Poovorawan Y; Tangkijvanich P
    Antivir Ther; 2017; 22(8):681-688. PubMed ID: 28291736
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Xie DY; Wang SM; Yang JM; Wang LH; Chen HY; Huai C; Shang J; Mao Q; Lei CL; Luo GH; Qian J; Lu DR
    World J Gastroenterol; 2016 Nov; 22(44):9813-9821. PubMed ID: 27956805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Treeprasertsuk S; Tanwandee T; Charatcharoenwitthaya P; Thongsawat S; Leerapun A; Piratvisuth T; Boonsirichan R; Bunchorntavakul C; Pattanasirigool C; Pornthisarn B; Tuntipanichteerakul S; Sripariwuth E; Jeamsripong W; Sanpajit T; Poovorawan Y; Komolmit P
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1257-1264. PubMed ID: 31030503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants of NTCP gene and hepatitis B vaccine failure in Taiwanese children of hepatitis B e antigen positive mothers.
    Chen YH; Tsuei DJ; Lai MW; Wen WH; Chiang CL; Wu JF; Chen HL; Hsu HY; Ni YH; Chang MH
    Hepatol Int; 2022 Aug; 16(4):789-798. PubMed ID: 35635688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
    Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection.
    Liaw YF; Lau GK; Kao JH; Gane E
    Dig Dis Sci; 2010 Oct; 55(10):2727-34. PubMed ID: 20238245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients.
    Liu WC; Wu IC; Chiu YC; Tseng KC; Chen CY; Chiu HC; Cheng PN; Chang TT
    Antiviral Res; 2020 Apr; 176():104719. PubMed ID: 32004619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.